These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 18635756

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L.
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA, Schumacher HR, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N.
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
    Hosoya T, Ohno I.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S27-34. PubMed ID: 21654267
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [Abstract] [Full Text] [Related]

  • 12. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
    Becker MA, Kisicki J, Khosravan R, Wu J, Mulford D, Hunt B, MacDonald P, Joseph-Ridge N.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
    Komoriya K, Hoshide S, Takeda K, Kobayashi H, Kubo J, Tsuchimoto M, Nakachi T, Yamanaka H, Kamatani N.
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
    [Abstract] [Full Text] [Related]

  • 14. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
    Bruce SP.
    Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
    [Abstract] [Full Text] [Related]

  • 15. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
    Grabowski B, Khosravan R, Wu JT, Vernillet L, Lademacher C.
    Br J Clin Pharmacol; 2010 Jul; 70(1):57-64. PubMed ID: 20642548
    [Abstract] [Full Text] [Related]

  • 16. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M, Yamauchi T, Ookura M, Matsuda Y, Tai K, Kishi S, Yoshida A, Iwasaki H, Nakamura T, Ueda T.
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S, RDEA594-111 Study Group.
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.